Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib (JAK1 Inhibitor): Atopic Dermatitis
- Braftovi® (encorafinib) + Erbitux® (cetuximab): 1st line BRAF-mutant Metastatic Colorectal Cancer
- Braftovi® (encorafinib) + Mektovi® (binimetinib) + Keytruda® (pembrolizumab): BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
- COVID-19 Vaccine: COVID-19 Infection (in collaboration with BioNTech)
- Fidanacogene elaparvovec (PF-06838435) (Gene Therapy, coagulation factor IX): Hemophilia
- Fordadistrogene movaparvovec (PF-06939926) (Gene Therapy): Duchenne Muscular Dystrophy
- Giroctocogene fitelparvovec (PF-07055480) (Gene Therapy, coagulation factor VIII): Hemophilia
- Marstacimab (PF-06741086) (Tissue Factor Pathway Inhibitor): Hemophilia
- Prophylactic Vaccine: Clostridioides difficile infection
- Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal infections (adult, pediatric)
- Prophylactic Vaccine: Meningococcal Infections (adolescent and young adults)
- Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
- Relugolix combination: Uterine Fibroids, Endometriosis
- Ritlecitinib (JAK3/TEC Inhibitor): Alopecia Areata
- Sasanlimab (PF-06801591) + BCG: Non-Muscle-Invasive Bladder Cancer
- Somatrogon (PF-06836922): Growth Hormone Deficiency (adult, pediatric)
- Talzenna® (talazoparib) + Xtandi® (enzalutamide): 1st Line Metastatic Castration-Resistant Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis; Cancer Pain
- Xtandi® (enzalutamide): Non-metastatic High-Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of May 4, 2021
- Discovery Projects
- 30Phase 1
- 38Phase 2
- 22Phase 3
- 10Registration
- Total100
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (E.U.)
Project advanced | Registration | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor | 1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Erbitux® (cetuximab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor and anti EGFR | 1st line BRAF-mutant Metastatic Colorectal Cancer | Phase 3 | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
recifercept Therapeutic Area: Rare Diseases Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy | Achondroplasia (Biologic) (ORPHAN - U.S.) | Phase 2 | New Molecular Entity | Biologic |
somatrogon (PF-06836922) Therapeutic Area: Rare Diseases Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Human Growth Hormone Agonist | Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) | Phase 3 | Product Enhancement | Biologic |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Inhibitor | Alopecia Areata | Phase 2 | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Inhibitor | Alopecia Areata (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
Xeljanz (tofacitinib) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor | Ankylosing Spondylitis (U.S., E.U.)
Project advanced | Registration | Product Enhancement | Small Molecule |
PF-07258669 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Melanocortin-4 receptor (MC4R) Antagonist | Anorexia
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical TYK2/JAK1 Inhibitor | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
PF-07038124 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical PDE4 Inhibitor | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
PF-07242813 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: CD1a molecule (CD1A) inhibitor | Atopic Dermatitis (Biologic) | Phase 1 | New Molecular Entity | Biologic |
abrocitinib (PF-04965842) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK1 Inhibitor | Atopic Dermatitis (PRIORITY REVIEW, BREAKTHROUGH - U.S., E.U.) | Registration | New Molecular Entity | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor and anti PD-1 | BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
Project advanced | Phase 3 | Product Enhancement | Small Molecule |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-07104091 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK2 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
